Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.

T. J. de Vries(Radboud University Nijmegen), G N van Muijen, Paul H.A. Quax(Leiden University Medical Center), Kiek Verrijp, Ulrich H. Weidle(Roche (Switzerland)), Hein W. Verspaget(Leiden University Medical Center), D. J. Ruiter(Radboud University Nijmegen), Jan H. Verheijen(Vesuvius (United Kingdom)), M. Denijn

PubMed

January 1, 1994

Cited by 149

Related Papers

N-ras mutations in human cutaneous melanoma from sun-exposed body sites.

|Molecular and Cellular Biology|1989|280

Aneurysmal bone cysts.A clinicopathological study of 105 cases

|Cancer|1977|269

c‐myc down‐regulates class I HLA expression in human melanomas.

|The EMBO Journal|1988|257

Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593.

|Journal of Clinical Oncology|1998|246

Final results of the EORTC 18871/DKG 80-1 randomised phase III trial

|European Journal of Cancer|2003|240